2a5u: Difference between revisions
From Proteopedia
Jump to navigationJump to search
New page: left|200px<br /> <applet load="2a5u" size="450" color="white" frame="true" align="right" spinBox="true" caption="2a5u, resolution 2.700Å" /> '''Crystal Structure ... |
No edit summary |
||
| Line 1: | Line 1: | ||
[[Image:2a5u.gif|left|200px]]<br /> | [[Image:2a5u.gif|left|200px]]<br /><applet load="2a5u" size="350" color="white" frame="true" align="right" spinBox="true" | ||
<applet load="2a5u" size=" | |||
caption="2a5u, resolution 2.700Å" /> | caption="2a5u, resolution 2.700Å" /> | ||
'''Crystal Structure of human PI3Kgamma complexed with AS605240'''<br /> | '''Crystal Structure of human PI3Kgamma complexed with AS605240'''<br /> | ||
==Overview== | ==Overview== | ||
Phosphoinositide 3-kinases (PI3K) have long been considered promising drug | Phosphoinositide 3-kinases (PI3K) have long been considered promising drug targets for the treatment of inflammatory and autoimmune disorders as well as cancer and cardiovascular diseases. But the lack of specificity, isoform selectivity and poor biopharmaceutical profile of PI3K inhibitors have so far hampered rigorous disease-relevant target validation. Here we describe the identification and development of specific, selective and orally active small-molecule inhibitors of PI3Kgamma (encoded by Pik3cg). We show that Pik3cg(-/-) mice are largely protected in mouse models of rheumatoid arthritis; this protection correlates with defective neutrophil migration, further validating PI3Kgamma as a therapeutic target. We also describe that oral treatment with a PI3Kgamma inhibitor suppresses the progression of joint inflammation and damage in two distinct mouse models of rheumatoid arthritis, reproducing the protective effects shown by Pik3cg(-/-) mice. Our results identify selective PI3Kgamma inhibitors as potential therapeutic molecules for the treatment of chronic inflammatory disorders such as rheumatoid arthritis. | ||
==About this Structure== | ==About this Structure== | ||
2A5U is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with QYT as [http://en.wikipedia.org/wiki/ligand ligand]. Active as [http://en.wikipedia.org/wiki/Phosphatidylinositol-4,5-bisphosphate_3-kinase Phosphatidylinositol-4,5-bisphosphate 3-kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.1.153 2.7.1.153] Full crystallographic information is available from [http:// | 2A5U is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=QYT:'>QYT</scene> as [http://en.wikipedia.org/wiki/ligand ligand]. Active as [http://en.wikipedia.org/wiki/Phosphatidylinositol-4,5-bisphosphate_3-kinase Phosphatidylinositol-4,5-bisphosphate 3-kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.1.153 2.7.1.153] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2A5U OCA]. | ||
==Reference== | ==Reference== | ||
| Line 31: | Line 30: | ||
[[Category: Rommel, C.]] | [[Category: Rommel, C.]] | ||
[[Category: Ruckle, T.]] | [[Category: Ruckle, T.]] | ||
[[Category: Schwarz, M | [[Category: Schwarz, M K.]] | ||
[[Category: Shaw, J.]] | [[Category: Shaw, J.]] | ||
[[Category: Vitte, P | [[Category: Vitte, P A.]] | ||
[[Category: Wymann, M | [[Category: Wymann, M P.]] | ||
[[Category: QYT]] | [[Category: QYT]] | ||
[[Category: pi3kg]] | [[Category: pi3kg]] | ||
[[Category: protein-inhibitor complex]] | [[Category: protein-inhibitor complex]] | ||
''Page seeded by [http:// | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 16:23:52 2008'' | ||
